Therapeutic Class
Monoclonal Antibodies (mAbs)
16 drug groups 6 with data 3,104 patients
| Drug group | Drugs | Patients |
|---|---|---|
| anti-CCR4 mAb Other mAbs | 1 | no data |
| anti-claudin 18.2 mAb Other mAbs | 1 | no data |
| anti-CSF1R mAb Other mAbs | 1 | no data |
| Anti-CTLA-4 mAb Checkpoint Inhibitors | 2 | 105 |
| Anti-EGFR mAb EGFR-Targeting | 3 | 394 |
| anti-EGFR/MET mAb Other mAbs | 1 | no data |
| anti-GD2 mAb Other mAbs | 2 | no data |
| anti-GITR mAb Other mAbs | 1 | combination data only |
| anti-HER2 mAb HER2-Targeting | 7 | 27 |
| Anti-idiotype vaccine mAb Other mAbs | 1 | no data |
| Anti-LAG-3 mAb Checkpoint Inhibitors | 1 | no data |
| Anti-PD-(L)1 mAb Checkpoint Inhibitors | 16 | 2,166 |
| Anti-PDGFRα mAb Other mAbs | 1 | 9 |
| Anti-RANKL mAb Other mAbs | 1 | no data |
| CD137 agonist mAb Other mAbs | 1 | no data |
| VEGF mAb Anti-VEGF | 2 | 403 |
Patients treated with the drug group as the sole drug class within 30 days of SRT. Combination therapies are shown on each group's page.